Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer

Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer

Bibliographic Details
Main Authors:	Jiang, Guiyang, Fan, Chuifeng, Zhang, Xiupeng, Dong, Qianze, Wang, Liang, Liu, Yang, Dai, Shundong, Yang, Lianhe, Zhang, Yong, Yu, Juanhan, Wang, Enhua
Format:	Online
Language:	English
Published:	Public Library of Science 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594188/

Similar Items

Promoter Methylation-Mediated Silencing of β-Catenin Enhances Invasiveness of Non-Small Cell Lung Cancer and Predicts Adverse Prognosis
by: Miao, Yuan, et al.
Published: (2014)

Pseudomyogenic hemangioendothelioma/epithelioid sarcoma-like hemangioendothelioma of the lower limb: report of a rare case
by: Fan, Chuifeng, et al.
Published: (2015)

Btbd7 contributes to reduced E-cadherin expression and predicts poor prognosis in non-small cell lung cancer
by: Fan, Chuifeng, et al.
Published: (2014)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
by: Derer, Stefanie, et al.
Published: (2013)

N-Terminal 1–54 Amino Acid Sequence and Armadillo Repeat Domain Are Indispensable for P120-Catenin Isoform 1A in Regulating E-Cadherin
by: Yu, Juanhan, et al.
Published: (2012)

P120-Catenin Isoforms 1 and 3 Regulate Proliferation and Cell Cycle of Lung Cancer Cells via β-Catenin and Kaiso Respectively
by: Jiang, Guiyang, et al.
Published: (2012)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
by: Wu, Shang-Gin, et al.
Published: (2011)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang, Fen, et al.
Published: (2012)

Impact of p120-catenin Isoforms 1A and 3A on Epithelial Mesenchymal Transition of Lung Cancer Cells Expressing E-cadherin in Different Subcellular Locations
by: Zhang, Yijun, et al.
Published: (2014)

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
by: Wang, Shuhang, et al.
Published: (2016)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
by: Li, X, et al.
Published: (2012)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition
by: Ottaiano, Alessandro, et al.
Published: (2013)

Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
by: Pedicini, Piernicola, et al.
Published: (2012)

Correction: modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
by: Pedicini, Piernicola, et al.
Published: (2012)

Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation–Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma
by: Kim, Chi Hong, et al.
Published: (2015)

Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis
by: Lesma, Elena, et al.
Published: (2015)

EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
by: Yang, Zu-Yao, et al.
Published: (2012)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
by: Wang, Wenxian, et al.
Published: (2016)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
by: Kuiper, J L, et al.
Published: (2016)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
by: Hung, Ming-Szu, et al.
Published: (2016)

EGFR transactivation contributes to neuroinflammation in Streptococcus suis meningitis
by: Yang, Xiao-Pei, et al.
Published: (2016)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
by: Yu, Jiang-Yong, et al.
Published: (2016)

The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors
by: Chang, Xiaofei, et al.
Published: (2013)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
by: Van Emburgh, Beth O., et al.
Published: (2016)

Research progress on criteria for discontinuation of EGFR inhibitor therapy
by: Zhuang, Hong-qing, et al.
Published: (2012)

EGFR mediates hyperlipidemia-induced renal injury via regulating inflammation and oxidative stress: the detrimental role and mechanism of EGFR activation
by: Fang, Qilu, et al.
Published: (2016)

Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer
by: WANG, CHENGDE, et al.
Published: (2015)

Tenascin turns on the EGFR
by: Jegalian, Karin
Published: (2001)

EGFR Mutations and Lung Cancer
Published: (2005)

ADAM metalloproteases and EGFR signalling
by: Gee, Julia MW, et al.
Published: (2003)

EGFR signaling in renal fibrosis
by: Zhuang, Shougang, et al.
Published: (2014)

EGFR Signaling in Liver Diseases
by: Komposch, Karin, et al.
Published: (2015)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang, Jun, et al.
Published: (2016)

Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells
by: Shin, Miyoung, et al.
Published: (2015)

HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth
by: Lu, Yuan, et al.
Published: (2016)

Combined EGFR and VEGFR versus Single EGFR Signaling Pathways Inhibition Therapy for NSCLC: A Systematic Review and Meta-Analysis
by: Zhang, Xinji, et al.
Published: (2012)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
by: LI, JING, et al.
Published: (2013)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
by: Wang, Xiaochun, et al.
Published: (2016)

Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy †
by: Sihver, Wiebke, et al.
Published: (2014)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
by: Wang, Zhijie, et al.
Published: (2015)